> top > docs > PubMed:27172902 > annotations

PubMed:27172902 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCoin-sentences

Id Subject Object Predicate Lexical cue
T1 0-166 Sentence denotes Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
T2 167-425 Sentence denotes Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood.
T3 426-590 Sentence denotes Here, we investigated the effect of cisplatin on the functionality of DCs and the changes in signaling pathways activated upon toll-like receptor (TLR) stimulation.
T4 591-765 Sentence denotes Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner.
T5 766-1053 Sentence denotes Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
T6 1054-1212 Sentence denotes This effect was dependent on the production of IL-10 from DCs, as neither DCs isolated from IL-10-/- mice nor IL-10-neutralized DCs generated tolerogenic DCs.
T7 1213-1467 Sentence denotes Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity.
T8 1468-1703 Sentence denotes Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
T9 1704-1942 Sentence denotes Taken together, our results suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-induced inflammatory conditions via abundant IL-10 production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.
T10 1943-2033 Sentence denotes This relationship may provide cancer cells with an opportunity to evade the immune system.

LitCoin-entities-OrganismTaxon-PD

Id Subject Object Predicate Lexical cue db_id
T1 1155-1159 OrganismTaxon denotes mice NCBItxid:10095|NCBItxid:10088

LitCoin-entities

Id Subject Object Predicate Lexical cue db_id
11281 0-9 ChemicalEntity denotes Cisplatin MESH:D002945
11282 61-64 GeneOrGeneProduct denotes TLR NCBIGene:13982
11283 105-110 GeneOrGeneProduct denotes IL-10 NCBIGene:16153
11284 203-212 ChemicalEntity denotes cisplatin MESH:D002945
11285 214-242 ChemicalEntity denotes cis-diamminedichloroplatinum MESH:D002945
11286 249-253 ChemicalEntity denotes CDDP MESH:D002945
11287 277-283 DiseaseOrPhenotypicFeature denotes cancer MESH:D009369
11288 323-332 ChemicalEntity denotes cisplatin MESH:D002945
11289 462-471 ChemicalEntity denotes cisplatin MESH:D002945
11290 553-571 GeneOrGeneProduct denotes toll-like receptor NCBIGene:13982
11291 573-576 GeneOrGeneProduct denotes TLR NCBIGene:13982
11292 591-600 ChemicalEntity denotes Cisplatin MESH:D002945
11293 670-674 GeneOrGeneProduct denotes CD80 NCBIGene:12519
11294 676-680 GeneOrGeneProduct denotes CD86 NCBIGene:12524
11295 682-700 GeneOrGeneProduct denotes MHC class I and II NCBIGene:14961|NCBIGene:14972
11296 796-799 GeneOrGeneProduct denotes TLR NCBIGene:13982
11297 810-819 ChemicalEntity denotes cisplatin MESH:D002945
11298 858-863 GeneOrGeneProduct denotes IL-10 NCBIGene:16153
11299 901-909 GeneOrGeneProduct denotes p38 MAPK NCBIGene:26416
11300 914-919 GeneOrGeneProduct denotes NF-κB NCBIGene:18033
11301 970-975 GeneOrGeneProduct denotes TNF-α NCBIGene:21926
11302 980-988 GeneOrGeneProduct denotes IL-12p70 NCBIGene:16185
11303 1005-1014 ChemicalEntity denotes cisplatin MESH:D002945
11304 1101-1106 GeneOrGeneProduct denotes IL-10 NCBIGene:16153
11305 1146-1151 GeneOrGeneProduct denotes IL-10 NCBIGene:16153
11306 1155-1159 OrganismTaxon denotes mice NCBITaxon:10090
11307 1164-1169 GeneOrGeneProduct denotes IL-10 NCBIGene:16153
11308 1258-1267 ChemicalEntity denotes cisplatin MESH:D002945
11309 1272-1290 ChemicalEntity denotes lipopolysaccharide MESH:D008070
11310 1292-1295 ChemicalEntity denotes LPS MESH:D008070
11311 1554-1559 GeneOrGeneProduct denotes IL-10 NCBIGene:16153
11312 1570-1573 GeneOrGeneProduct denotes CD3 NCBIGene:12501
11313 1574-1577 GeneOrGeneProduct denotes CD4 NCBIGene:12504
11314 1578-1583 GeneOrGeneProduct denotes LAG-3 NCBIGene:16768
11315 1584-1589 GeneOrGeneProduct denotes CD49b NCBIGene:16398
11316 1590-1594 GeneOrGeneProduct denotes CD25 NCBIGene:16184
11317 1595-1600 GeneOrGeneProduct denotes Foxp3 NCBIGene:20371
11318 1667-1672 GeneOrGeneProduct denotes Foxp3 NCBIGene:20371
11319 1745-1754 ChemicalEntity denotes cisplatin MESH:D002945
11320 1801-1812 ChemicalEntity denotes TLR agonist
11321 1821-1833 DiseaseOrPhenotypicFeature denotes inflammatory MESH:D007249
11322 1858-1863 GeneOrGeneProduct denotes IL-10 NCBIGene:16153
11323 1973-1979 DiseaseOrPhenotypicFeature denotes cancer MESH:D009369

LitCoin_Mondo

Id Subject Object Predicate Lexical cue mondo_id
T1 277-283 DiseaseOrPhenotypicFeature denotes cancer 0004992
T2 1763-1781 DiseaseOrPhenotypicFeature denotes immune-suppressive 0007816
T3 1973-1979 DiseaseOrPhenotypicFeature denotes cancer 0004992

LitCoin-GeneOrGeneProduct-v0

Id Subject Object Predicate Lexical cue
T1 0-9 GeneOrGeneProduct denotes Cisplatin
T2 10-17 GeneOrGeneProduct denotes induces
T3 40-45 GeneOrGeneProduct denotes cells
T4 91-101 GeneOrGeneProduct denotes production
T5 105-110 GeneOrGeneProduct denotes IL-10
T6 139-142 GeneOrGeneProduct denotes Tr1
T7 152-156 GeneOrGeneProduct denotes cell
T8 157-165 GeneOrGeneProduct denotes immunity
T9 176-180 GeneOrGeneProduct denotes many
T10 203-212 GeneOrGeneProduct denotes cisplatin
T11 244-246 GeneOrGeneProduct denotes II
T12 323-332 GeneOrGeneProduct denotes cisplatin
T13 391-396 GeneOrGeneProduct denotes cells
T14 462-471 GeneOrGeneProduct denotes cisplatin
T15 538-547 GeneOrGeneProduct denotes activated
T16 553-571 GeneOrGeneProduct denotes toll-like receptor
T17 591-600 GeneOrGeneProduct denotes Cisplatin
T18 618-627 GeneOrGeneProduct denotes regulated
T19 646-658 GeneOrGeneProduct denotes cell surface
T20 670-674 GeneOrGeneProduct denotes CD80
T21 676-680 GeneOrGeneProduct denotes CD86
T22 682-693 GeneOrGeneProduct denotes MHC class I
T23 698-700 GeneOrGeneProduct denotes II
T24 709-718 GeneOrGeneProduct denotes regulated
T25 738-742 GeneOrGeneProduct denotes in a
T26 810-819 GeneOrGeneProduct denotes cisplatin
T27 839-847 GeneOrGeneProduct denotes markedly
T28 858-863 GeneOrGeneProduct denotes IL-10
T29 864-874 GeneOrGeneProduct denotes production
T30 883-893 GeneOrGeneProduct denotes activation
T31 901-909 GeneOrGeneProduct denotes p38 MAPK
T32 1005-1014 GeneOrGeneProduct denotes cisplatin
T33 1015-1023 GeneOrGeneProduct denotes mediated
T34 1087-1097 GeneOrGeneProduct denotes production
T35 1101-1106 GeneOrGeneProduct denotes IL-10
T36 1146-1151 GeneOrGeneProduct denotes IL-10
T37 1155-1159 GeneOrGeneProduct denotes mice
T38 1164-1169 GeneOrGeneProduct denotes IL-10
T39 1258-1267 GeneOrGeneProduct denotes cisplatin
T40 1350-1362 GeneOrGeneProduct denotes inducing the
T41 1380-1383 GeneOrGeneProduct denotes Th1
T42 1401-1406 GeneOrGeneProduct denotes cells
T43 1453-1457 GeneOrGeneProduct denotes cell
T44 1458-1466 GeneOrGeneProduct denotes immunity
T45 1537-1541 GeneOrGeneProduct denotes cell
T46 1554-1559 GeneOrGeneProduct denotes IL-10
T47 1570-1573 GeneOrGeneProduct denotes CD3
T48 1574-1577 GeneOrGeneProduct denotes CD4
T49 1578-1583 GeneOrGeneProduct denotes LAG-3
T50 1584-1589 GeneOrGeneProduct denotes CD49b
T51 1590-1594 GeneOrGeneProduct denotes CD25
T52 1595-1600 GeneOrGeneProduct denotes Foxp3
T53 1602-1605 GeneOrGeneProduct denotes Tr1
T54 1606-1611 GeneOrGeneProduct denotes cells
T55 1667-1672 GeneOrGeneProduct denotes Foxp3
T56 1687-1691 GeneOrGeneProduct denotes cell
T57 1745-1754 GeneOrGeneProduct denotes cisplatin
T58 1755-1762 GeneOrGeneProduct denotes induces
T59 1763-1769 GeneOrGeneProduct denotes immune
T60 1813-1820 GeneOrGeneProduct denotes induced
T61 1858-1863 GeneOrGeneProduct denotes IL-10
T62 1864-1874 GeneOrGeneProduct denotes production
T63 1895-1915 GeneOrGeneProduct denotes cell differentiation
T64 1932-1935 GeneOrGeneProduct denotes Tr1
T65 1936-1941 GeneOrGeneProduct denotes cells
T66 1980-1985 GeneOrGeneProduct denotes cells
T67 2019-2025 GeneOrGeneProduct denotes immune

LitCoin-GeneOrGeneProduct-v2

Id Subject Object Predicate Lexical cue
T1 0-9 GeneOrGeneProduct denotes Cisplatin
T2 105-110 GeneOrGeneProduct denotes IL-10
T3 152-156 GeneOrGeneProduct denotes cell
T4 157-165 GeneOrGeneProduct denotes immunity
T5 203-212 GeneOrGeneProduct denotes cisplatin
T6 323-332 GeneOrGeneProduct denotes cisplatin
T7 462-471 GeneOrGeneProduct denotes cisplatin
T8 553-571 GeneOrGeneProduct denotes toll-like receptor
T9 591-600 GeneOrGeneProduct denotes Cisplatin
T10 646-658 GeneOrGeneProduct denotes cell surface
T11 670-674 GeneOrGeneProduct denotes CD80
T12 676-680 GeneOrGeneProduct denotes CD86
T13 682-693 GeneOrGeneProduct denotes MHC class I
T14 810-819 GeneOrGeneProduct denotes cisplatin
T15 858-863 GeneOrGeneProduct denotes IL-10
T16 901-909 GeneOrGeneProduct denotes p38 MAPK
T17 1005-1014 GeneOrGeneProduct denotes cisplatin
T18 1101-1106 GeneOrGeneProduct denotes IL-10
T19 1146-1151 GeneOrGeneProduct denotes IL-10
T20 1164-1169 GeneOrGeneProduct denotes IL-10
T21 1258-1267 GeneOrGeneProduct denotes cisplatin
T22 1453-1457 GeneOrGeneProduct denotes cell
T23 1458-1466 GeneOrGeneProduct denotes immunity
T24 1537-1541 GeneOrGeneProduct denotes cell
T25 1554-1559 GeneOrGeneProduct denotes IL-10
T26 1578-1583 GeneOrGeneProduct denotes LAG-3
T27 1584-1589 GeneOrGeneProduct denotes CD49b
T28 1590-1594 GeneOrGeneProduct denotes CD25
T29 1595-1600 GeneOrGeneProduct denotes Foxp3
T30 1667-1672 GeneOrGeneProduct denotes Foxp3
T31 1687-1691 GeneOrGeneProduct denotes cell
T32 1745-1754 GeneOrGeneProduct denotes cisplatin
T33 1858-1863 GeneOrGeneProduct denotes IL-10
T34 1895-1915 GeneOrGeneProduct denotes cell differentiation

LitCoin-Disease-MeSH

Id Subject Object Predicate Lexical cue originalLabel
T1 277-283 DiseaseOrPhenotypicFeature denotes cancer D009369
T2 1821-1833 DiseaseOrPhenotypicFeature denotes inflammatory DISEASE
T3 1973-1979 DiseaseOrPhenotypicFeature denotes cancer D009369

LitCoin-GeneOrGeneProduct-v3

Id Subject Object Predicate Lexical cue
T1 61-64 GeneOrGeneProduct denotes TLR
T2 105-110 GeneOrGeneProduct denotes IL-10
T3 553-571 GeneOrGeneProduct denotes toll-like receptor
T4 573-576 GeneOrGeneProduct denotes TLR
T5 670-674 GeneOrGeneProduct denotes CD80
T6 676-680 GeneOrGeneProduct denotes CD86
T7 682-693 GeneOrGeneProduct denotes MHC class I
T8 796-799 GeneOrGeneProduct denotes TLR
T9 858-863 GeneOrGeneProduct denotes IL-10
T10 901-909 GeneOrGeneProduct denotes p38 MAPK
T11 1101-1106 GeneOrGeneProduct denotes IL-10
T12 1146-1151 GeneOrGeneProduct denotes IL-10
T13 1164-1169 GeneOrGeneProduct denotes IL-10
T14 1554-1559 GeneOrGeneProduct denotes IL-10
T15 1578-1583 GeneOrGeneProduct denotes LAG-3
T16 1584-1589 GeneOrGeneProduct denotes CD49b
T17 1590-1594 GeneOrGeneProduct denotes CD25
T18 1595-1600 GeneOrGeneProduct denotes Foxp3
T19 1667-1672 GeneOrGeneProduct denotes Foxp3
T20 1801-1804 GeneOrGeneProduct denotes TLR
T21 1858-1863 GeneOrGeneProduct denotes IL-10

LitCoin_Mondo_095

Id Subject Object Predicate Lexical cue mondo_id
T1 398-401 DiseaseOrPhenotypicFeature denotes DCs 0010155
T2 496-499 DiseaseOrPhenotypicFeature denotes DCs 0010155
T3 609-612 DiseaseOrPhenotypicFeature denotes DCs 0010155
T4 828-831 DiseaseOrPhenotypicFeature denotes DCs 0010155
T5 1049-1052 DiseaseOrPhenotypicFeature denotes DCs 0010155
T6 1112-1115 DiseaseOrPhenotypicFeature denotes DCs 0010155
T7 1128-1131 DiseaseOrPhenotypicFeature denotes DCs 0010155
T8 1182-1185 DiseaseOrPhenotypicFeature denotes DCs 0010155
T9 1208-1211 DiseaseOrPhenotypicFeature denotes DCs 0010155
T10 1228-1231 DiseaseOrPhenotypicFeature denotes DCs 0010155
T11 1292-1295 DiseaseOrPhenotypicFeature denotes LPS 0019508
T12 1423-1426 DiseaseOrPhenotypicFeature denotes DCs 0010155
T13 1794-1797 DiseaseOrPhenotypicFeature denotes DCs 0010155

LitCoin-MeSH-Disease-2

Id Subject Object Predicate Lexical cue ID:
T1 277-283 DiseaseOrPhenotypicFeature denotes cancer D009369
T2 1821-1833 DiseaseOrPhenotypicFeature denotes inflammatory DISEASE
T3 1973-1979 DiseaseOrPhenotypicFeature denotes cancer D009369

LitCoin-MONDO_bioort2019

Id Subject Object Predicate Lexical cue #label
T1 277-283 DiseaseOrPhenotypicFeature denotes cancer D009369
T2 1973-1979 DiseaseOrPhenotypicFeature denotes cancer D009369

LitCoin-Chemical-MeSH-CHEBI

Id Subject Object Predicate Lexical cue ID:
T1 0-9 ChemicalEntity denotes Cisplatin http://purl.obolibrary.org/obo/CHEBI_27899
T2 203-212 ChemicalEntity denotes cisplatin D002945|http://purl.obolibrary.org/obo/CHEBI_27899
T4 214-242 ChemicalEntity denotes cis-diamminedichloroplatinum http://purl.obolibrary.org/obo/CHEBI_27899
T5 249-253 ChemicalEntity denotes CDDP http://purl.obolibrary.org/obo/CHEBI_27899
T6 323-332 ChemicalEntity denotes cisplatin D002945|http://purl.obolibrary.org/obo/CHEBI_27899
T8 462-471 ChemicalEntity denotes cisplatin D002945|http://purl.obolibrary.org/obo/CHEBI_27899
T10 591-600 ChemicalEntity denotes Cisplatin http://purl.obolibrary.org/obo/CHEBI_27899
T11 810-819 ChemicalEntity denotes cisplatin D002945|http://purl.obolibrary.org/obo/CHEBI_27899
T13 1005-1014 ChemicalEntity denotes cisplatin D002945|http://purl.obolibrary.org/obo/CHEBI_27899
T15 1258-1267 ChemicalEntity denotes cisplatin D002945|http://purl.obolibrary.org/obo/CHEBI_27899
T17 1272-1290 ChemicalEntity denotes lipopolysaccharide D008070|http://purl.obolibrary.org/obo/CHEBI_16412
T19 1292-1295 ChemicalEntity denotes LPS http://purl.obolibrary.org/obo/CHEBI_89981|http://purl.obolibrary.org/obo/CHEBI_52603|http://purl.obolibrary.org/obo/CHEBI_16412|D008070
T23 1578-1581 ChemicalEntity denotes LAG http://purl.obolibrary.org/obo/CHEBI_73526
T24 1745-1754 ChemicalEntity denotes cisplatin D002945|http://purl.obolibrary.org/obo/CHEBI_27899
T26 1801-1812 ChemicalEntity denotes TLR agonist ChemicalEntity

LitCoin-NCBITaxon-2

Id Subject Object Predicate Lexical cue
T1 214-217 OrganismTaxon denotes cis
T2 1155-1159 OrganismTaxon denotes mice

LitCoin-training-merged

Id Subject Object Predicate Lexical cue #label ID:
T26 1801-1812 ChemicalEntity denotes TLR agonist ChemicalEntity
T24 1745-1754 ChemicalEntity denotes cisplatin http://purl.obolibrary.org/obo/CHEBI_27899|D002945
T23 1578-1581 ChemicalEntity denotes LAG http://purl.obolibrary.org/obo/CHEBI_73526
T19 1292-1295 ChemicalEntity denotes LPS D008070|http://purl.obolibrary.org/obo/CHEBI_16412|http://purl.obolibrary.org/obo/CHEBI_52603|http://purl.obolibrary.org/obo/CHEBI_89981
T17 1272-1290 ChemicalEntity denotes lipopolysaccharide http://purl.obolibrary.org/obo/CHEBI_16412|D008070
T15 1258-1267 ChemicalEntity denotes cisplatin http://purl.obolibrary.org/obo/CHEBI_27899|D002945
T13 1005-1014 ChemicalEntity denotes cisplatin http://purl.obolibrary.org/obo/CHEBI_27899|D002945
T11 810-819 ChemicalEntity denotes cisplatin http://purl.obolibrary.org/obo/CHEBI_27899|D002945
T10 591-600 ChemicalEntity denotes Cisplatin http://purl.obolibrary.org/obo/CHEBI_27899
T8 462-471 ChemicalEntity denotes cisplatin http://purl.obolibrary.org/obo/CHEBI_27899|D002945
T6 323-332 ChemicalEntity denotes cisplatin http://purl.obolibrary.org/obo/CHEBI_27899|D002945
T5 249-253 ChemicalEntity denotes CDDP http://purl.obolibrary.org/obo/CHEBI_27899
T4 214-242 ChemicalEntity denotes cis-diamminedichloroplatinum http://purl.obolibrary.org/obo/CHEBI_27899
T2 203-212 ChemicalEntity denotes cisplatin http://purl.obolibrary.org/obo/CHEBI_27899|D002945
T1 0-9 ChemicalEntity denotes Cisplatin http://purl.obolibrary.org/obo/CHEBI_27899
T21 1858-1863 GeneOrGeneProduct denotes IL-10
T20 1801-1804 GeneOrGeneProduct denotes TLR
T92486 1667-1672 GeneOrGeneProduct denotes Foxp3
T18 1595-1600 GeneOrGeneProduct denotes Foxp3
T55141 1590-1594 GeneOrGeneProduct denotes CD25
T16 1584-1589 GeneOrGeneProduct denotes CD49b
T79627 1578-1583 GeneOrGeneProduct denotes LAG-3
T14 1554-1559 GeneOrGeneProduct denotes IL-10
T60535 1164-1169 GeneOrGeneProduct denotes IL-10
T12 1146-1151 GeneOrGeneProduct denotes IL-10
T44547 1101-1106 GeneOrGeneProduct denotes IL-10
T92895 901-909 GeneOrGeneProduct denotes p38 MAPK
T9 858-863 GeneOrGeneProduct denotes IL-10
T5090 796-799 GeneOrGeneProduct denotes TLR
T7 682-693 GeneOrGeneProduct denotes MHC class I
T51747 676-680 GeneOrGeneProduct denotes CD86
T63261 670-674 GeneOrGeneProduct denotes CD80
T38223 573-576 GeneOrGeneProduct denotes TLR
T3 553-571 GeneOrGeneProduct denotes toll-like receptor
T31928 105-110 GeneOrGeneProduct denotes IL-10
T64036 61-64 GeneOrGeneProduct denotes TLR
T77520 1973-1979 DiseaseOrPhenotypicFeature denotes cancer D009369
T47382 277-283 DiseaseOrPhenotypicFeature denotes cancer D009369
T51520 1155-1159 OrganismTaxon denotes mice
T44809 214-217 OrganismTaxon denotes cis

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-166 Sentence denotes Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
T2 167-425 Sentence denotes Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood.
T3 426-590 Sentence denotes Here, we investigated the effect of cisplatin on the functionality of DCs and the changes in signaling pathways activated upon toll-like receptor (TLR) stimulation.
T4 591-765 Sentence denotes Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner.
T5 766-1053 Sentence denotes Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
T6 1054-1212 Sentence denotes This effect was dependent on the production of IL-10 from DCs, as neither DCs isolated from IL-10-/- mice nor IL-10-neutralized DCs generated tolerogenic DCs.
T7 1213-1467 Sentence denotes Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity.
T8 1468-1703 Sentence denotes Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
T9 1704-1942 Sentence denotes Taken together, our results suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-induced inflammatory conditions via abundant IL-10 production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.
T10 1943-2033 Sentence denotes This relationship may provide cancer cells with an opportunity to evade the immune system.
T1 0-166 Sentence denotes Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
T2 167-425 Sentence denotes Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood.
T3 426-590 Sentence denotes Here, we investigated the effect of cisplatin on the functionality of DCs and the changes in signaling pathways activated upon toll-like receptor (TLR) stimulation.
T4 591-765 Sentence denotes Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner.
T5 766-1053 Sentence denotes Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
T6 1054-1212 Sentence denotes This effect was dependent on the production of IL-10 from DCs, as neither DCs isolated from IL-10-/- mice nor IL-10-neutralized DCs generated tolerogenic DCs.
T7 1213-1467 Sentence denotes Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity.
T8 1468-1703 Sentence denotes Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
T9 1704-1942 Sentence denotes Taken together, our results suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-induced inflammatory conditions via abundant IL-10 production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.
T10 1943-2033 Sentence denotes This relationship may provide cancer cells with an opportunity to evade the immune system.